HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• CAR T cells may transform blood cancer treatment, but concerns remain about safety, availability
• Missed research opportunities, real-time data sharing remain key obstacles for cancer moonshot Wafik S. El-Deiry, MD, PhD, FACP
• American Thyroid Association elects new officers
• CAR T cells produce high response rates in ALL, but concerns about side effects remain
• Cedars-Sinai names deputy director of integrated oncology
• Checkpoint inhibitor therapy more economical, safe than CAR T cells in pediatric leukemia
• Four named to leadership roles at University of Michigan Comprehensive Cancer Center
• Fred Hutchinson Cancer Research Center hires executive vice president
• Fred Hutch/University of Washington Cancer Consortium names executive director
• Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL
• Identification of biomarkers may allow for better management of GVHD
• Keytruda improves OS in advanced bladder cancer, study closes early
• Leukemia & Lymphoma Society announces launch of genomic profiling–based trial for AML
• Lurie Comprehensive Cancer Center names associate director for clinical sciences research
• Moonshot report: Expedited delivery of therapies, improved patient access among keys to accelerating progress against cancer
• NYU Langone names chief of hematology, medical oncology
• Pediatric regimens for ALL show promise in adults
• Progress in GVHD management improves efficacy of allogeneic HSCT
• Radiation Oncology Institute awards two grants
• Roswell Park Cancer Institute deputy director re-elected task force co-chair
• Thoracic malignancies specialist joins Fox Chase Cancer Center
• University Hospitals Cleveland Medical Center neurosurgeon receives award
• Vanderbilt researcher receives VA award
• ‘Very good evidence’ suggests breast implant–associated lymphoma is underdiagnosed
• Yale Cancer Center names director, physician in chief
• Doing the same thing over and over again but expecting different results: It’s time to move on John Sweetenham, MD, FRCP, FACP
• FDA approves Keytruda for first-line treatment of PD-L1–expressing metastatic NSCLC
• FDA approves Lartruvo for soft tissue sarcoma
• FDA clears Ortho Vision Max blood analyzer
• FDA modifies Tarceva indication for NSCLC
• AABB updates guidelines on red blood cell transfusion threshold, storage duration
• Active monitoring, treatment confer comparable prostate cancer–specific survival
• ANNEXA-4: Reversal agent effective in patients with acute major bleeding after Factor Xa inhibitor use
• Anticoagulation increases intracranial hemorrhage risk in patients with glioma
• Arginine deprivation shows promise for malignant pleural mesothelioma
• Bone marrow biopsy does not add value to PET/CT staging of DLBCL
• Chemoradiotherapy does not prolong OS in locally advanced pancreatic cancer
• Combined immunotherapy associated with pneumonitis
• Daratumumab plus lenalidomide, dexamethasone prolongs PFS in relapsed, refractory multiple myeloma
• DLBCL survivors at risk for long-term sarcopenia, visceral obesity
• DNA testing may reveal unknown genetic ancestry in triple-negative breast cancer
• Elotuzumab combination exhibits benefit for relapsed, refractory multiple myeloma
• Guideline revisions lead to increase in HER-2–positive breast cancers, possible false positives
• High-dose methotrexate improves outcomes in children with B-ALL
• HPV genotypes not targeted in vaccines have similar malignant potential
• Hyperthyroidism linked to lower recurrent VTE risk among elderly patients
• Incidence of early-stage prostate cancer continues to decline after USPSTF recommendations
• Ipilimumab shows promise for patients who relapse following HSCT
• Khorana Risk Score not predictive of VTE in lung cancer
• Limited treatment safe, successful for pediatric patients with lymphocyte-predominant Hodgkin lymphoma
• Lymph node metastases predict survival after esophagogastric cancer treatment
• MACRA final rule offers more flexibility, but concerns remain about implications
• Mantle cell lymphoma progression during ibrutinib treatment leads to poor outcomes
• Molecular, genetic factors influence treatment response in children, adolescents with medulloblastoma
• Mortality risk persists beyond 30 years following Wilms’ tumor diagnosis
• Mutation status affects cisplatin sensitivity in advanced germ cell tumors
• NCHS data brief: 20% decline in children’s cancer death rate ‘builds upon 3 decades of progress’
• New surgical technique improves staging accuracy of node-positive breast cancer
• Nivolumab maintains health-related quality of life for patients with advanced melanoma
• Nomogram effectively predicts DFS, OS in retroperitoneal sarcomas
• Nonsurgical surveillance safe, cost-effective for head, neck cancer
• Novel fluorescent agent may identify ovarian lesions during surgery
• Oophorectomy may increase colorectal cancer risk
• Opioid-induced constipation medication may improve OS in advanced cancer
• Oropharyngeal cancer incidence on the rise among elderly patients
• Ovarian reserves lower in BRCA1 mutation carriers
• Patient-reported outcomes after unrelated donor transplant better with bone marrow than peripheral blood
• Patients with CML have life expectancy comparable to that of general population
• Pemetrexed plus gefitinib improves PFS in EGFR–mutated NSCLC
• PET may be overused to detect lung, esophageal cancer recurrence
• Physician-related factors affect likelihood of breast preservation after second event
• Pretransplantation mogamulizumab increases risk for GVHD–related mortality
• Retinoic acid plus arsenic trioxide demonstrate antileukemic effect in acute promyelocytic leukemia
• Robatumumab shows efficacy in Ewing sarcoma, fails primary endpoint
• Severe fatigue prevents social reintegration among Hodgkin lymphoma survivors
• Sufficient plasma vitamin D levels linked to improved pancreatic cancer survival
• Survival good, postoperative complications frequent for pediatric DTC
• Survivors of fusion-negative sarcoma at increased risk for second malignancies
• US veterans have increased frequency of HCC at autopsy
• Vinblastine shows promise as first-line treatment for pediatric gliomas
• Abemaciclib effective for Ki67 reduction in certain postmenopausal women with breast cancer
• Abiraterone acetate may yield clinical benefit in subset of women with ovarian cancer
• Adjuvant ipilimumab extends survival in stage III melanoma
• Alisertib may benefit certain patients with neuroendocrine prostate cancer
• Atezolizumab prolongs OS in previously treated NSCLC
• Brachytherapy alone can control intermediate-risk prostate cancer
• Ceritinib extends PFS in pretreated patients with ALK–rearranged NSCLC
• Dabrafenib shows promise for BRAF V600–mutated pediatric low-grade gliomas
• Dabrafenib, trametinib improve 3-year OS in advanced BRAF–mutated melanoma
• Derived neutrophil-to-lymphocyte ratio predicts DFS in early breast cancer
• First-line pembrolizumab plus chemotherapy improves response rates, PFS in advanced NSCLC
• FOLFOXIRI plus bevacizumab improves response rate, PFS in advanced colorectal cancer
• Fulvestrant extends PFS in certain postmenopausal women with breast cancer
• Hypofractionated radiation therapy offers shorter treatment for poor-performance NSCLC
• Neoadjuvant chemoradiotherapy improves survival in locally advanced esophageal squamous cell carcinoma
• Neoadjuvant nivolumab feasible, safe in early-stage resectable NSCLC
• Nintedanib improves PFS, not OS, in refractory, metastatic colorectal cancer
• Nivolumab effective in pretreated metastatic or surgically unresectable urothelial cancer
• Nivolumab may improve patient-reported outcomes in HNSCC
• Radiation boost after whole breast radiation therapy for DCIS reduces local tumor recurrence
• Selinexor demonstrates antitumor activity in heavily pretreated ovarian, endometrial cancers
• Selumetinib plus docetaxel fails to extend survival in KRAS–mutant NSCLC
• Standard neoadjuvant chemotherapy improves OS, RFS in soft tissue sarcoma
• Stereotactic body radiation therapy use increases, yields improved early-stage NSCLC survival
• Will CAR T cells always be reserved for late lines of therapy?